Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axe

Showing results (281-290 of 290) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 290 results.
Environmental Science & Technology|July 21, 2011
Hypoxia is increasing in the coastal zone of the Baltic SeaDaniel J Conley, Jacob Carstensen, Juris Aigars, et al.
Journal of Medicinal Chemistry|July 1, 2008
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activityCheryl A Grice, Kevin L Tays, Brad M Savall, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1Alice Lee-Dutra, Danielle K Wiener, Kristen L Arienti, et al.
The Journal of Biological Chemistry|October 8, 2003
Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectorsJun-Young Choe, Scott W Nelson, Kristen L Arienti, et al.
Nature|August 20, 2005
Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesisRebecca A Wingert, Jenna L Galloway, Bruce Barut, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Contemporary Clinical Trials|December 13, 2021
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 daysErin K McCreary, J Ryan Bariola, Tami Minnier, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Pageof 29

Showing results (281-290 of 290) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 290 results.
Environmental Science & Technology|July 21, 2011
Hypoxia is increasing in the coastal zone of the Baltic SeaDaniel J Conley, Jacob Carstensen, Juris Aigars, et al.
Journal of Medicinal Chemistry|July 1, 2008
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activityCheryl A Grice, Kevin L Tays, Brad M Savall, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1Alice Lee-Dutra, Danielle K Wiener, Kristen L Arienti, et al.
The Journal of Biological Chemistry|October 8, 2003
Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectorsJun-Young Choe, Scott W Nelson, Kristen L Arienti, et al.
Nature|August 20, 2005
Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesisRebecca A Wingert, Jenna L Galloway, Bruce Barut, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Contemporary Clinical Trials|December 13, 2021
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 daysErin K McCreary, J Ryan Bariola, Tami Minnier, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Pageof 29